Trial Profile
A retrospective study to evaluate the effectiveness of Oritavancin in patients with Acute bacterial skin and skin structure infections : A real world data
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Apr 2017
Price :
$35
*
At a glance
- Drugs Oritavancin (Primary) ; Dalbavancin; Daptomycin; Vancomycin
- Indications Bacterial infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
- Focus Therapeutic Use
- 01 Mar 2017 Primary endpoint (Success (cured or improved) at 5-30 days after the course of antibiotic therapy has been completed) has been met, according to the results published in the Infectious Diseases and Therapy
- 01 Mar 2017 Results published in the Infectious Diseases and Therapy
- 29 Sep 2016 New trial record